Centrient CEO Sees New Opportunities From Astral Acquisition
Rex Clements Sets Out Expectations For Integration Of Sterile Injectables Specialist
Acquiring Astral SteriTech will open up significant new capabilities in sterile injectables for Centrient while also offering an opportunity to expand the reach of the Indian firm’s products through Centrient’s infrastructure, CEO Rex Clements tells Generics Bulletin in an exclusive interview.
You may also be interested in...
Sandoz has completed the acquisition of GSK’s cephalosporin antibiotics business which includes the Zinnat, Zinacef and Fortum brands in more than 100 markets. Commenting as the deal closed, Sandoz CEO Richard Saynor emphasized the importance of investing in antibiotics.
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Antibiotics specialist Centrient has struck a deal to acquire India’s Astral SteriTech in a move that will expand its portfolio to include sterile injectable finished-dose products.